Hamza Hashmi, Myeloma and Cellular Therapy Physician at Memorial Sloan Kettering Cancer Center, shared a post on X:
“ASH25: Presented by Beatrice Razzo, Al Garfall as poster but IMO as imp as any oral abstract LimiTEC with Tec cessation after 6-9m for RRMM pts in VGPR+ led to 12m PFS ~65%
- n=50, 4 pLOT, 90% TCR, 20% w prior BCMA (ide-cel + BlenRep, 50% with no response to BCMA-DT!!)
- 60% in CR prior to cessation of Tec, median fu 12m after cessation, 12m PFS 68%, OS 90%, PFS in those w prior
- BCMA BCMA loss/mutation most likely mech of resistance but salvaged by Talq
Imp to see if B cell recovery a/w hyogamm, infections IVIG QOL, MMRF HORIZON study evaluating similar concept Most PD occurred <6m post cessation, all those with PD <12m post cessation had no response to Tec; I wonder if we extend Tec cessation to only after 12m, it will identify pts who would benefit from reinitiation vs alt salvage.”
More posts featuring Hamza Hashmi.
